Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (82) 82
oncology (67) 67
female (56) 56
index medicus (56) 56
male (47) 47
middle aged (47) 47
aged (39) 39
lung neoplasms - genetics (36) 36
adult (35) 35
respiratory system (35) 35
lung neoplasms - pathology (33) 33
carcinoma, non-small-cell lung - genetics (29) 29
prognosis (27) 27
lung neoplasms - drug therapy (25) 25
carcinoma, non-small-cell lung - pathology (24) 24
carcinoma, non-small-cell lung - drug therapy (22) 22
lung cancer (22) 22
chemotherapy (21) 21
immunohistochemistry (18) 18
mutation (18) 18
receptor, epidermal growth factor - genetics (18) 18
cancer (17) 17
lung cancer, non-small cell (17) 17
aged, 80 and over (16) 16
erlotinib (16) 16
neoplasm staging (16) 16
gefitinib (15) 15
non-small cell lung cancer (15) 15
care and treatment (13) 13
lung neoplasms - metabolism (13) 13
article (12) 12
follow-up studies (12) 12
treatment outcome (12) 12
receptor, epidermal growth factor - antagonists & inhibitors (11) 11
research (11) 11
adenocarcinoma (10) 10
beer (10) 10
biochemistry (10) 10
chemistry (10) 10
compositions or test papers therefor (10) 10
condition-responsive control in microbiological orenzymological processes (10) 10
disease-free survival (10) 10
enzymology (10) 10
gene copy number (10) 10
in situ hybridization, fluorescence (10) 10
lung neoplasms - mortality (10) 10
lung neoplasms - surgery (10) 10
measuring or testing processes involving enzymes, nucleicacids or microorganisms (10) 10
metallurgy (10) 10
microbiology (10) 10
mutation or genetic engineering (10) 10
processes of preparing such compositions (10) 10
protein kinase inhibitors - therapeutic use (10) 10
spirits (10) 10
survival (10) 10
survival rate (10) 10
vinegar (10) 10
wine (10) 10
adenocarcinoma - genetics (9) 9
antineoplastic agents - therapeutic use (9) 9
carcinoma (9) 9
carcinoma, non-small-cell lung - mortality (9) 9
carcinoma, non-small-cell lung - surgery (9) 9
gene dosage (9) 9
hematology, oncology and palliative medicine (9) 9
investigating or analysing materials by determining theirchemical or physical properties (9) 9
lung neoplasms - diagnosis (9) 9
measuring (9) 9
nsclc (9) 9
physics (9) 9
survival analysis (9) 9
testing (9) 9
antineoplastic combined chemotherapy protocols - therapeutic use (8) 8
carcinoma, non-small-cell lung - metabolism (8) 8
expression (8) 8
gene expression regulation, neoplastic (8) 8
lung neoplasms - therapy (8) 8
mutations (8) 8
prospective studies (8) 8
quinazolines - therapeutic use (8) 8
tumors (8) 8
afatinib (7) 7
analysis (7) 7
biomarkers, tumor - analysis (7) 7
breast-cancer (7) 7
cell lung-cancer (7) 7
crizotinib (7) 7
disease progression (7) 7
epidermal growth factor receptor (7) 7
lung cancer, small cell (7) 7
metastasis (7) 7
predictive value of tests (7) 7
previously treated patients (7) 7
tyrosine kinase inhibitors (7) 7
activating mutations (6) 6
carcinoma, squamous cell - genetics (6) 6
combination (6) 6
diagnosis (6) 6
gefitinib sensitivity (6) 6
health aspects (6) 6
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Whole Brain Radiotherapy for Patients with Non–Small Cell Lung Cancer with EGFR Mutations—Why and When?
by Dziadziuszko, Rafal
Journal of Thoracic Oncology, ISSN 1556-0864, 10/2016, Volume 11, Issue 10, pp. 1604 - 1605
ONCOLOGY | RESPIRATORY SYSTEM | Lung Neoplasms - radiotherapy | Brain | Carcinoma, Non-Small-Cell Lung - radiotherapy | Receptor, Epidermal Growth Factor - genetics | Mutation | Humans
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Radiotherapy and targeted drugs
by Dziadziuszko, Rafal
Lung Cancer, ISSN 0169-5002, 2012, Volume 77, pp. S2 - S2
Hematology, Oncology and Palliative Medicine | Pulmonary/Respiratory
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Alectinib versus Crizotinib in Untreated ALK-Positive Non–Small-Cell Lung Cancer
by Peters, Solange and Camidge, D. Ross and Shaw, Alice T and Gadgeel, Shirish and Ahn, Jin S and Kim, Dong-Wan and Ou, Sai-Hong I and Pérol, Maurice and Dziadziuszko, Rafal and Rosell, Rafael and Zeaiter, Ali and Mitry, Emmanuel and Golding, Sophie and Balas, Bogdana and Noe, Johannes and Morcos, Peter N and Mok, Tony and ALEX Trial Investigators
The New England Journal of Medicine, ISSN 0028-4793, 08/2017, Volume 377, Issue 9, pp. 829 - 838
Alectinib, a potent ALK tyrosine kinase inhibitor, was more effective and somewhat less toxic than crizotinib when used as primary therapy in patients with ALK... 
RESISTANT | MEDICINE, GENERAL & INTERNAL | MODELS | ANTITUMOR-ACTIVITY | INHIBITOR ALECTINIB | CHEMOTHERAPY | Lung Neoplasms - drug therapy | Pyrazoles - therapeutic use | Follow-Up Studies | Lung Neoplasms - mortality | Humans | Middle Aged | Male | Antineoplastic Agents - therapeutic use | Protein Kinase Inhibitors - adverse effects | Central Nervous System Neoplasms - secondary | Young Adult | Pyridines - adverse effects | Anaplastic Lymphoma Kinase | Antineoplastic Agents - adverse effects | Aged, 80 and over | Receptor Protein-Tyrosine Kinases - antagonists & inhibitors | Adult | Female | Receptor Protein-Tyrosine Kinases - analysis | Pyrazoles - adverse effects | Pyridines - therapeutic use | Crizotinib | Carbazoles - adverse effects | Kaplan-Meier Estimate | Carcinoma, Non-Small-Cell Lung - mortality | Disease-Free Survival | Animals | Piperidines - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Piperidines - adverse effects | Intention to Treat Analysis | Carbazoles - therapeutic use | Carcinoma, Non-Small-Cell Lung - drug therapy | Central Nervous System Neoplasms - drug therapy | Drugs | Care and treatment | Analysis | Comparative analysis | Lung cancer, Non-small cell | Health aspects | Systemic diseases | Toxicity | Lung cancer | Central nervous system | Non-small cell lung carcinoma | Oncology | Nervous system | Metastasis | Radiation therapy | Patients | Lymphoma | Cancer therapies | Survival | Mutation | Protein-tyrosine kinase | Drug dosages | Tumors | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Rociletinib in EGFR-Mutated Non–Small-Cell Lung Cancer
by Sequist, Lecia V and Soria, Jean-Charles and Goldman, Jonathan W and Wakelee, Heather A and Gadgeel, Shirish M and Varga, Andrea and Papadimitrakopoulou, Vassiliki and Solomon, Benjamin J and Oxnard, Geoffrey R and Dziadziuszko, Rafal and Aisner, Dara L and Doebele, Robert C and Galasso, Cathy and Garon, Edward B and Heist, Rebecca S and Logan, Jennifer and Neal, Joel W and Mendenhall, Melody A and Nichols, Suzanne and Piotrowska, Zofia and Wozniak, Antoinette J and Raponi, Mitch and Karlovich, Chris A and Jaw-Tsai, Sarah and Isaacson, Jeffrey and Despain, Darrin and Matheny, Shannon L and Rolfe, Lindsey and Allen, Andrew R and Camidge, D. Ross
The New England Journal of Medicine, ISSN 0028-4793, 04/2015, Volume 372, Issue 18, pp. 1700 - 1709
Patients with non–small-cell lung cancer and mutated epidermal growth factor receptors who develop resistance to EGFR inhibitors through a particular mutation... 
TYROSINE KINASE INHIBITORS | MEDICINE, GENERAL & INTERNAL | PHASE-II TRIAL | GEFITINIB | ADENOCARCINOMA | ACQUIRED-RESISTANCE | MUTATIONS | AFATINIB | ERLOTINIB | CHEMOTHERAPY | Lung Neoplasms - drug therapy | Receptor, Epidermal Growth Factor - genetics | Humans | Middle Aged | Lung Neoplasms - pathology | Male | Antineoplastic Agents - administration & dosage | Protein Kinase Inhibitors - adverse effects | Acrylamides - pharmacokinetics | Dose-Response Relationship, Drug | Hyperglycemia - chemically induced | Antineoplastic Agents - adverse effects | Female | Carcinoma, Non-Small-Cell Lung - pathology | Lung Neoplasms - genetics | Protein Kinase Inhibitors - pharmacokinetics | Carcinoma, Non-Small-Cell Lung - genetics | Pyrimidines - administration & dosage | Protein Kinase Inhibitors - administration & dosage | Drug Resistance, Neoplasm - genetics | Acrylamides - administration & dosage | Pyrimidines - adverse effects | Pyrimidines - pharmacokinetics | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Mutation | Acrylamides - adverse effects | Clinical trials | Care and treatment | Usage | Diagnosis | Lung cancer, Non-small cell | Hyperglycemia | Chemotherapy | Epidermal growth factor | Inhibitor drugs | Epidermal growth factor receptors | Lung cancer | Genes | Non-small cell lung carcinoma | Antitumor activity | Pharmacokinetics | Patients | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Welcome to the 4th European lung cancer conference
by Felip, Enriqueta and Dziadziuszko, Rafal
Journal of Thoracic Oncology, ISSN 1556-0864, 2014, Volume 9, Issue 4, p. S6
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Indications and limitations of chemotherapy and targeted agents in non-small cell lung cancer brain metastases
by Zimmermann, Stefan and Dziadziuszko, Rafal and Peters, Solange
Cancer Treatment Reviews, ISSN 0305-7372, 2014, Volume 40, Issue 6, pp. 716 - 722
Abstract Lung cancer is characterized by the highest incidence of solid tumor-related brain metastases, which are reported with a growing incidence during the... 
Hematology, Oncology and Palliative Medicine | Non small cell lung cancer (NSCLC) | Driver oncogenes | Targeted treatment | Brain metastasis | Stereotactic radiotherapy | 1ST-LINE CHEMOTHERAPY | DOSE WEEKLY ERLOTINIB | CEREBRAL METASTASES | RADIATION-THERAPY | TYROSINE KINASE INHIBITORS | BREAST-CANCER | PHASE-II TRIAL | NERVOUS-SYSTEM METASTASES | STEREOTACTIC RADIOSURGERY | ONCOLOGY | LEPTOMENINGEAL METASTASES | Erlotinib Hydrochloride | Receptor, Epidermal Growth Factor - genetics | Carcinoma, Non-Small-Cell Lung - surgery | Prognosis | Humans | Antineoplastic Combined Chemotherapy Protocols - pharmacokinetics | Radiosurgery | Receptor, Epidermal Growth Factor - drug effects | Lung Neoplasms - pathology | Treatment Outcome | Brain Neoplasms - drug therapy | Brain Neoplasms - surgery | Incidence | Brain Neoplasms - secondary | Carcinoma, Non-Small-Cell Lung - secondary | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Quinazolines - administration & dosage | Carcinoma, Non-Small-Cell Lung - drug therapy | Molecular Targeted Therapy - methods | Blood-Brain Barrier | Lung cancer, Small cell | Chemotherapy | Metastasis | Lung cancer, Non-small cell | Cancer
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Authors' Reply
by Camidge, D Ross and Dziadziuszko, Rafal and ALEX Investigators
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 09/2019, Volume 14, Issue 9, p. e196
Journal Article
Details down arrow
8. Full Text Molecular Predictors of Outcome With Gefitinib in a Phase III Placebo-Controlled Study in Advanced Non–Small-Cell Lung Cancer
by Fred R. Hirsch and Marileila Varella-Garcia and Paul A. Bunn Jr and Wilbur A. Franklin and Rafal Dziadziuszko and Nick Thatcher and Alex Chang and Purvish Parikh and José Rodrigues Pereira and Tudor Ciuleanu and Joachim von Pawel and Claire Watkins and Angela Flannery and Gillian Ellison and Emma Donald and Lucy Knight and Dinah Parums and Nicholas Botwood and Brian Holloway
Journal of Clinical Oncology, ISSN 0732-183X, 11/2006, Volume 24, Issue 31, pp. 5034 - 5042
Purpose The phase III Iressa Survival Evaluation in Lung Cancer (ISEL) trial compared gefitinib with placebo in 1,692 patients with refractory advanced non -... 
TRIAL | SURVIVAL | GROWTH-FACTOR-RECEPTOR | ONCOLOGY | TYROSINE KINASE | SENSITIVITY | B-RAF | GENE COPY NUMBER | ACTIVATING MUTATIONS | ERLOTINIB | PREVIOUSLY TREATED PATIENTS | Immunohistochemistry | Lung Neoplasms - drug therapy | Predictive Value of Tests | Receptor, Epidermal Growth Factor - genetics | Phosphorylation | Proto-Oncogene Proteins p21(ras) | Carcinoma, Non-Small-Cell Lung - chemistry | ras Proteins | Humans | Middle Aged | Gene Expression Regulation, Neoplastic | Male | Antineoplastic Agents - therapeutic use | Adult | Female | Lung Neoplasms - chemistry | Biomarkers, Tumor - analysis | In Situ Hybridization, Fluorescence | Proto-Oncogene Proteins - genetics | Treatment Outcome | Receptor, Epidermal Growth Factor - analysis | Proto-Oncogene Proteins B-raf - genetics | Quinazolines - therapeutic use | Proto-Oncogene Proteins c-akt - analysis | Survival Analysis | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Mutation
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Insulin-like Growth Factor Receptor 1 (IGF1R) Gene Copy Number Is Associated With Survival in Operable Non–Small-Cell Lung Cancer: A Comparison Between IGF1R Fluorescent In Situ Hybridization, Protein Expression, and mRNA Expression
by Rafal Dziadziuszko and Daniel T. Merrick and Samir E. Witta and Adelita D. Mendoza and Barbara Szostakiewicz and Amelia Szymanowska and Witold Rzyman and Katarzyna Dziadziuszko and Jacek Jassem and Paul A. Bunn, Jr and Marileila Varella-Garcia and Fred R. Hirsch
Journal of Clinical Oncology, ISSN 0732-183X, 05/2010, Volume 28, Issue 13, pp. 2174 - 2180
Purpose The purpose of this study was to characterize insulin-like growth factor-1 receptor (IGF1R) protein expression, mRNA expression, and gene copy number... 
BREAST-CANCER | ONCOLOGY | PATHWAY | IGFR-1 | ANTIBODY CP-751,871 | RESISTANCE | HETERODIMERIZATION | COMBINATION | GEFITINIB SENSITIVITY | CHEMOTHERAPY | ERLOTINIB | Immunohistochemistry | Receptor, Epidermal Growth Factor - genetics | Receptor, IGF Type 1 - analysis | Carcinoma, Non-Small-Cell Lung - chemistry | Lung Neoplasms - mortality | Tissue Array Analysis | Carcinoma, Squamous Cell - genetics | Humans | Middle Aged | Gene Expression Regulation, Neoplastic | RNA, Messenger - analysis | Aneuploidy | Carcinoma, Squamous Cell - surgery | Male | Carcinoma, Squamous Cell - mortality | Time Factors | Aged, 80 and over | Adult | Female | Adenocarcinoma - genetics | Carcinoma, Large Cell - genetics | Adenocarcinoma - chemistry | Lung Neoplasms - genetics | Carcinoma, Large Cell - chemistry | Carcinoma, Non-Small-Cell Lung - surgery | Lung Neoplasms - chemistry | Risk Assessment | Carcinoma, Non-Small-Cell Lung - genetics | Risk Factors | Kaplan-Meier Estimate | Proportional Hazards Models | Carcinoma, Squamous Cell - chemistry | In Situ Hybridization, Fluorescence | Treatment Outcome | Gene Dosage | Reverse Transcriptase Polymerase Chain Reaction | Carcinoma, Non-Small-Cell Lung - mortality | Receptor, IGF Type 1 - genetics | Disease-Free Survival | Carcinoma, Large Cell - surgery | Pulmonary Surgical Procedures | Lung Neoplasms - surgery | Aged | Neoplasm Staging | Adenocarcinoma - surgery | Original Reports | Thor19 | Bc8 | To20
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text Resistance Mechanisms to Targeted Therapies in ROS1(+) and ALK(+) Non-small Cell Lung Cancer
by McCoach, CE and Le, AT and Gowan, K and Jones, K and Schubert, L and Doak, A and Estrada-Bernal, A and Davies, KD and Merrick, DT and Bunn, PA and Purcell, WT and Dziadziuszko, R and Varella-Garcia, M and Aisner, DL and Camidge, DR and Doebele, RC
CLINICAL CANCER RESEARCH, ISSN 1078-0432, 07/2018, Volume 24, Issue 14, pp. 3334 - 3347
Purpose: Despite initial benefit from tyrosine kinase inhibitors (TKIs), patients with advanced non-small cell lung cancer (NSCLC) harboring ALK (ALK(+)) and... 
MUTATION CONFERS RESISTANCE | ONCOLOGY | OVERCOMES CRIZOTINIB RESISTANCE | EML4-ALK FUSION | COPY NUMBER | IN-SITU HYBRIDIZATION | GENE REARRANGEMENT | LYMPHOMA KINASE ALK | TUMOR-CELLS | INHIBITOR | NSCLC PATIENTS | Tyrosine | Neuregulin 1 | Epidermal growth factor receptors | Genes | Lung cancer | Non-small cell lung carcinoma | Drug resistance | Kinases | Patients | ErbB-2 protein | Gene fusion | Genetic screening | Gene sequencing | Polymerase chain reaction | β-catenin | Ret protein | Experimental design | Mutation | Protein-tyrosine kinase | Deoxyribonucleic acid--DNA | DNA sequencing | Cancer | Proto-oncogenes | non-small cell lung cancer | ALK | tyrosine kinase inhibitor | ROS1 | acquired resistance
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
11. Full Text A Randomized, Phase II, Biomarker-Selected Study Comparing Erlotinib to Erlotinib Intercalated With Chemotherapy in First-Line Therapy for Advanced Non–Small-Cell Lung Cancer
by Fred R. Hirsch and Fairooz Kabbinavar and Tim Eisen and Renato Martins and Fredrick M. Schnell and Rafal Dziadziuszko and Katherine Richardson and Frank Richardson and Bret Wacker and David W. Sternberg and Jason Rusk and Wilbur A. Franklin and Marileila Varella-Garcia and Paul A. Bunn, Jr and D. Ross Camidge
Journal of Clinical Oncology, ISSN 0732-183X, 09/2011, Volume 29, Issue 26, pp. 3567 - 3573
Purpose Erlotinib prolongs survival in patients with advanced non-small-cell lung cancer (NSCLC). We report the results of a randomized, phase II study of... 
CARBOPLATIN | GEFITINIB | PROTEIN | GENE | ONCOLOGY | COMBINATION | EXPRESSION | PACLITAXEL | Erlotinib Hydrochloride | Lung Neoplasms - drug therapy | Receptor, Epidermal Growth Factor - genetics | Proto-Oncogene Proteins p21(ras) | Cadherins - metabolism | Vimentin - metabolism | Humans | Biomarkers, Pharmacological | Antineoplastic Combined Chemotherapy Protocols - adverse effects | ras Proteins - metabolism | Carboplatin - adverse effects | Receptor, Epidermal Growth Factor - metabolism | Quinazolines - administration & dosage | Paclitaxel - administration & dosage | Proto-Oncogene Proteins - metabolism | Drug Administration Schedule | Carboplatin - administration & dosage | Paclitaxel - adverse effects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Quinazolines - therapeutic use | Quinazolines - adverse effects | Survival Analysis | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Carcinoma, Non-Small-Cell Lung - blood | Lung Neoplasms - blood | Carcinoma, Non-Small-Cell Lung - drug therapy | Original Reports | Thor11
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
12. Full Text NSCLC molecular testing in Central and Eastern European countries
by Ryska, Ales and Berzinec, Peter and Brcic, Luka and Cufer, Tanja and Dziadziuszko, Rafal and Gottfried, Maya and Kovalszky, Ilona and Olszewski, Włodzimierz and Oz, Buge and Plank, Lukas and Timar, Jozsef
BMC Cancer, ISSN 1471-2407, 03/2018, Volume 18, Issue 1, pp. 269 - 8
Background: The introduction of targeted treatments for subsets of non-small cell lung cancer (NSCLC) has highlighted the importance of accurate molecular... 
ALK rearrangements | Molecular testing | EGFR mutations | Central eastern European region | Non-small cell lung cancer | ESMO CONSENSUS CONFERENCE | IN-SITU HYBRIDIZATION | EXTERNAL QUALITY ASSESSMENT | PATHOLOGY | EGFR | CELL LUNG-CANCER | TYROSINE KINASE INHIBITORS | ONCOLOGY | MUTATION | INTERNATIONAL-ASSOCIATION | ALK GENE REARRANGEMENTS | Usage | Care and treatment | Gene mutations | Biopsy | Molecular diagnostic techniques | Research | Diagnosis | Lung cancer, Non-small cell | Immunohistochemistry | Cytogenetics
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
13. Full Text A phase 1, open-label, dose-escalation trial of oral TSR-011 in patients with advanced solid tumours and lymphomas
by Lin, Chia-Chi and Arkenau, Hendrik-Tobias and Lu, Sharon and Sachdev, Jasgit and de Castro Carpeño, Javier and Mita, Monica and Dziadziuszko, Rafal and Su, Wu-Chou and Bobilev, Dmitri and Hughes, Lorraine and Chan, Jian and Zhang, Zhi-Yi and Weiss, Glen J
British Journal of Cancer, ISSN 0007-0920, 2019, Volume 121, Issue 2, pp. 131 - 138
BACKGROUND: Anaplastic lymphoma kinase (ALK) gene rearrangements are oncogenic drivers in non-small-cell lung cancer (NSCLC). TSR-011 is a dual ALK and... 
ONCOLOGY | LUNG | CRIZOTINIB RESISTANCE | Slopes | Tropomyosin | Lung cancer | Non-small cell lung carcinoma | Pharmacology | Kinases | Lymphoma | Patients | Refractory materials | Inhibitors | Safety | Solid tumors | Pharmacokinetics | Protein-tyrosine kinase | Tumors | Targeted therapies
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
14. Full Text Management of brain metastases in non-small cell lung cancer in the era of tyrosine kinase inhibitors
by Wrona, Anna and Dziadziuszko, Rafał and Jassem, Jacek
Cancer Treatment Reviews, ISSN 0305-7372, 12/2018, Volume 71, pp. 59 - 67
Lung cancer represents the most common cause of brain dissemination. Oncogene-addicted ( - and -positive) non-small cell lung cancers (NSCLCs) are... 
Stereotactic radiosurgery | ALK inhibitors | Brain metastases | EGFR inhibitors | Whole brain radiotherapy | Non-small cell lung cancer | POSTOPERATIVE STEREOTACTIC RADIOSURGERY | PHASE-III | EGFR MUTATION | INTRACRANIAL EFFICACY | CEREBROSPINAL-FLUID | RADIATION-THERAPY | HIGH-DOSE ERLOTINIB | ONCOLOGY | LEPTOMENINGEAL METASTASES | CNS METASTASES | SINGLE METASTASES | Carcinoma, Non-Small-Cell Lung - pathology | Lung Neoplasms - genetics | Crizotinib - therapeutic use | ErbB Receptors - antagonists & inhibitors | Carcinoma, Non-Small-Cell Lung - genetics | Humans | Lung Neoplasms - pathology | Antineoplastic Agents - therapeutic use | Brain Neoplasms - drug therapy | Brain Neoplasms - secondary | Protein Kinase Inhibitors - therapeutic use | Crizotinib - pharmacology | Antineoplastic Agents - pharmacology | Brain Neoplasms - mortality | Brain Neoplasms - radiotherapy | Anaplastic Lymphoma Kinase - antagonists & inhibitors | Molecular Targeted Therapy - methods | Oncogenes | Tyrosine | Brain | Chemotherapy | Radiosurgery | Phenols | Lung cancer, Small cell | Metastasis | Lung cancer, Non-small cell | Health aspects | Cancer
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
15. Full Text Crizotinib Therapy for Advanced Lung Adenocarcinoma and a ROS1 Rearrangement: Results From the EUROS1 Cohort
by Mazieres, Julien and Zalcman, Gerard and Crino, Lucio and Biondani, Pamela and Barlesi, Fabrice and Filleron, Thomas and Dingemans, Anne-Marie C and Lena, Herve and Monnet, Isabelle and Rothschild, Sacha I and Cappuzzo, Federico and Besse, Benjamin and Thiberville, Luc and Rouviere, Damien and Dziadziuszko, Rafal and Smit, Egbert F and Wolf, Jurgen and Spirig, Christian and Pecuchet, Nicolas and Leenders, Frauke and Heuckmann, Johannes M and Diebold, Joachim and Milia, Julie D and Thomas, Roman K and Gautschi, Oliver
Journal of Clinical Oncology, ISSN 0732-183X, 03/2015, Volume 33, Issue 9, pp. 992 - +
Purpose Approximately 1% of lung adenocarcinomas are driven by oncogenic ROS1 rearrangement. Crizotinib is a potent inhibitor of both ROS1 and ALK kinase... 
RET | GLIOBLASTOMA | FUSION | GENE | ONCOLOGY | ACQUIRED-RESISTANCE | PATIENT | NEVER-SMOKERS | CLINICOPATHOLOGICAL ANALYSIS | HER2 MUTATION | CANCER | Immunohistochemistry | Lung Neoplasms - drug therapy | Translocation, Genetic | Off-Label Use | Pyrazoles - therapeutic use | Prospective Studies | Humans | Middle Aged | Male | Protein-Tyrosine Kinases - genetics | Adult | Female | Adenocarcinoma - genetics | Retrospective Studies | Pyridines - therapeutic use | Lung Neoplasms - genetics | Carcinoma, Non-Small-Cell Lung - genetics | Europe | In Situ Hybridization, Fluorescence | Proto-Oncogene Proteins - genetics | Treatment Outcome | Adenocarcinoma - drug therapy | Disease Progression | Disease-Free Survival | Protein Kinase Inhibitors - therapeutic use | Gene Rearrangement | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Mutation | Life Sciences | Cancer
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
16. Full Text Galectin-9 in non-small cell lung cancer
by He, Yayi and Jia, Keyi and Dziadziuszko, Rafal and Zhao, Sha and Zhang, Xiaoshen and Deng, Juan and Wang, Hao and Hirsch, Fred R and Zhou, Caicun
Lung Cancer, ISSN 0169-5002, 10/2019, Volume 136, pp. 80 - 85
Lung cancer has the highest incidence and fatality among all cancers. Our research analyzed the expression of galectin-9 on non-small cell lung cancer (NSCLC)... 
PD-L1 | Galectin-9 | TILs | NSCLC | PD-1 | Immunohistochemistry | Medical colleges | Cell death | Analysis | Lung cancer, Small cell | T cells | Lung cancer, Non-small cell | Tumors
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
17. Full Text Increased plasma concentration of 4-pyridone-3-carboxamide-1-ß-D-ribonucleoside (4PYR) in lung cancer. Preliminary studies
by Jablonska, Patrycja and Mierzejewska, Paulina and Kutryb-Zajac, Barbara and Rzyman, Witold and Dziadziuszko, Rafal and Polanska, Joanna and Sitkiewicz, Magdalena and Smolenski, Ryszard T and Slominska, Ewa M
Nucleosides, Nucleotides and Nucleic Acids, ISSN 1525-7770, 10/2019, Volume 38, Issue 10, pp. 781 - 787
4-pyridone-3-carboxamide-1-β-D-ribonucleoside (4PYR) is a new nicotinamide derivative, which is potentially toxic to the endothelium. Dysfunction of the... 
lung cancer | endothelium | 4-pyridone-3-carboxamide-1-β-D-ribonucleoside | Nicotinamide | 1-methylnicotinamide | UREMIC TOXINS | ERYTHROCYTES | BIOCHEMISTRY & MOLECULAR BIOLOGY | 4-pyridone-3-carboxamide-1-beta-D-ribonucleoside | FAILURE | NADPH | Cell proliferation | Squamous cell carcinoma | Arginine | Invasiveness | Lung cancer | Glycolysis | Inflammation | Endothelium | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights